RadioMedix and OncoBeta announce exclusive distribution agreement for W/Re-188 generators in U.S. and Canada
10 févr. 2020 16h00 HE
|
RadioMedix Inc.
Houston, TX, USA, and Garching, Germany, Feb. 10, 2020 (GLOBE NEWSWIRE) -- RadioMedix, and OncoBeta today announced the execution of an exclusive distribution agreement for the next generation of...
RadioMedix selected for 2019-2020 NIH SBIR/STTR Commercialization Accelerator Program (CAP)
03 janv. 2020 00h00 HE
|
RadioMedix Inc.
Houston, Jan. 03, 2020 (GLOBE NEWSWIRE) -- RadioMedix Inc. is pleased to announce that the company has been selected for the 2019-2020 Commercialization Accelerator Program (CAP) by the National...
RadioMedix received $2.0 M SBIR Phase II Contract award from NCI NIH for the targeted alpha-emitter therapy of neuroendocrine cancers.
22 janv. 2019 10h00 HE
|
RadioMedix Inc.
Houston (TX), Jan. 22, 2019 (GLOBE NEWSWIRE) -- RadioMedix Inc. is pleased to announce that the company has been awarded a two-years, $2.0 M Phase II SBIR contract award by the NIH NCI...
RadioMedix and Curium Announce FDA Fast Track Designation For 64Cu-Dotatate.
09 janv. 2019 01h00 HE
|
RadioMedix Inc.
Houston, TX and St. Louis, MO, Jan. 09, 2019 (GLOBE NEWSWIRE) -- RadioMedix Inc. and its commercial partner Curium announced today that their investigational diagnostic radiopharmaceutical,...
RadioMedix and Orano Med receive FDA Orphan Drug Designation for AlphaMedix (TM) for the treatment of neuroendocrine tumors
13 nov. 2018 10h00 HE
|
RadioMedix Inc.
Houston (TX U.S.), Courbevoie (France), Nov. 13, 2018 (GLOBE NEWSWIRE) -- RadioMedix Inc. (a Texas-based clinical stage biotechnology company) and Orano Med (a nuclear biotechnology company)...
Curium and RadioMedix Announce Exclusive Global Agreement for 64Cu-Dotatate Development
26 août 2018 21h00 HE
|
Curium
St. Louis and Houston, Aug. 26, 2018 (GLOBE NEWSWIRE) -- Curium and RadioMedix Inc. announce an exclusive agreement to develop and commercialize 64Cu-Dotatate, an investigational positron emission...
RadioMedix and AREVA Med announce initiation of Phase 1 clinical trial of AlphaMedix(TM), a Targeted Alpha Therapy for patients with neuroendocrine tumors
10 janv. 2018 05h00 HE
|
RadioMedix Inc.
Houston, TX (USA) and Courbevoie (France), Jan. 10, 2018 (GLOBE NEWSWIRE) -- RadioMedix Inc. and AREVA Med today announced the initiation in the United States of Phase 1 trial for AlphaMedixTM in...
RadioMedix Inc. and AREVA Med Announce Completion of the Exploratory Clinical Trial of 203Pb-AR-RMX in patients expressing somatostatin receptor positive neuroendocrine tumors
22 juin 2017 16h00 HE
|
RadioMedix Inc.
Houston, TX; Plano, TX, June 22, 2017 (GLOBE NEWSWIRE) -- RadioMedix Inc and AREVA Med announced today the completion of the exploratory clinical trial evaluating the biodistribution...
First U.S. Multi-center Investigational Clinical Trial of 177 Lu PSMA-617 Targeted Radioligand Therapy in Metastatic Castration Resistant Prostate Cancer Receives FDA Clearance
06 févr. 2017 06h00 HE
|
RadioMedix Inc.
Houston, TX; Los Angeles, CA, Feb. 06, 2017 (GLOBE NEWSWIRE) -- RadioMedix, Excel Diagnostics and Nuclear Oncology Center (EDNOC), and the Ahmanson Translational Imaging...
RadioMedix and AREVA Med – SBIR NCI Contract Grant awarded to develop targeted alpha-emitter therapy of neuroendocrine tumors with lead-212
01 nov. 2016 01h00 HE
|
RadioMedix Inc.
Houston TX, Nov. 01, 2016 (GLOBE NEWSWIRE) -- RadioMedix Inc. (Houston TX) and AREVA Med (Plano TX) announced today that they have been awarded a collaborative Small Business Innovation...